COPENHAGEN, Denmark, October 8, 2019 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the initiation of the first-in-human trial of MVA-BNŽ WEV, a prophylactic vaccine candidate against the equine encephalitis virus - a rare, but potentially deadly illness. The program, which is funded by the United States Department of Defense (DOD) Joint Project Manager for Chemical, Biological, Radiation, and Nuclear Medical (JPM CBRN Medical) is a multi-year agreement valued up to USD 36 million and aims to develop a vaccine against three separate strains of the equine encephalitis virus, Eastern (EEEV), Venezuelan (VEEV), and Western (WEEV), for which there are currently no preventative...
|
